ArticleBritish journal of pharmacology2007
Identification of an antagonist that selectively blocks the activity of prostamides (prostaglandin-ethanolamides) in the feline iris.
Article in British journal of pharmacology, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 61 citations in OpenAlex.
- Deletion of the gene encoding prostamide/prostaglandin F synthase reveals an important role in regulating intraocular pressure.Prostaglandins, leukotrienes, and essential fatty acids · 2021Article
- The affinity, intrinsic activity and selectivity of a structurally novel EPBritish journal of pharmacology · 2019Article
- Patient considerations in ocular hypertension: role of bimatoprost ophthalmic solution.Clinical ophthalmology (Auckland, N.Z.) · 2017Review
- Identification of prostamides, fatty acyl ethanolamines, and their biosynthetic precursors in rabbit cornea.Journal of lipid research · 2015Article
- Prostamide F(2) α receptor antagonism combined with inhibition of FAAH may block the pro-inflammatory mediators formed following selective FAAH inhibition.British journal of pharmacology · 2014Article
- Anandamide-derived prostamide F2α negatively regulates adipogenesis.The Journal of biological chemistry · 2013Article
- The biodisposition and hypertrichotic effects of bimatoprost in mouse skin.Experimental dermatology · 2013Article
- Biasing the prostaglandin F2α receptor responses toward EGFR-dependent transactivation of MAPK.Molecular endocrinology (Baltimore, Md.) · 2012Article
- Endocannabinoid oxygenation by cyclooxygenases, lipoxygenases, and cytochromes P450: cross-talk between the eicosanoid and endocannabinoid signaling pathways.Chemical reviews · 2011Review
- The effect of dorzolamide 2% on circadian intraocular pressure in cats with primary congenital glaucoma.Veterinary ophthalmology · 2011Article
- Roles of affinity and lipophilicity in the slow kinetics of prostanoid receptor antagonists on isolated smooth muscle preparations.British journal of pharmacology · 2011Article
- Cellular basis for bimatoprost effects on human conventional outflow.Investigative ophthalmology & visual science · 2010Article
- Structural determinants for calcium mobilization by prostaglandin E2 and prostaglandin F2alpha glyceryl esters in RAW 264.7 cells and H1819 cells.Prostaglandins & other lipid mediators · 2010Article
- Prostanoid receptor antagonists: development strategies and therapeutic applications.British journal of pharmacology · 2009Review
- Role of prostaglandins and specific place in therapy of bimatoprost in the treatment of elevated intraocular pressure and ocular hypertension: A closer look at the agonist properties of bimatoprost and the prostamides.Clinical ophthalmology (Auckland, N.Z.) · 2009Article
- Identification and pharmacological characterization of the prostaglandin FP receptor and FP receptor variant complexes.British journal of pharmacology · 2008Article
- Prostamides (prostaglandin-ethanolamides) and their pharmacology.British journal of pharmacology · 2008Review
- Endogenous Bioactive Lipids and the Regulation of Conventional Outflow Facility.Expert review of ophthalmology · 2008Article
- The complications of promiscuity: endocannabinoid action and metabolism.British journal of pharmacology · 2007Review
- The contribution of cyclooxygenase-2 to endocannabinoid metabolism and action.British journal of pharmacology · 2007Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
background and purposeThe prostamides (prostaglandin-ethanolamides) and prostaglandin (PG) glyceryl esters are biosynthesized by COX-2 from the respective endocannabinoids anandamide and 2-arachidonyl glycerol. Agonist studies suggest that their pharmacologies are unique and unrelated to prostanoid receptors. This concept was further investigated using antagonists. EXPERIMENTAL APPROACH: The isolated feline iris was used as a key preparation, where prostanoid FP receptors and prostamide activity co-exist. Activity at human recombinant FP and other prostanoid receptors was determined using stable transfectants. KEY
resultsIn the feline iris, AGN 204396 produced a rightward shift of the dose-response curves for prostamide F2alpha and the prostamide F2alpha analog bimatoprost but did not block the effects of PGF2alpha and synthetic FP receptor agonists. Studies on human recombinant prostanoid receptors confirmed that AGN 204396 did not behave as a prostanoid FP receptor antagonist. AGN 204396 exhibited no antagonism at DP and EP1-4, but was a highly effective TP receptor antagonist. Contrary to expectation, the FP receptor antagonist AL-8810 efficaciously contracted the cat iris. AGN 204396 did not affect AL-8810 induced contractions, demonstrating that AL-8810 and AGN 204396 are pharmacologically distinct. Unlike AL-8810, the ethylamide derivate of AL-8810 was not an agonist. Al-8810 did not block prostamide F2alpha activity. Finally, AGN 204396 did not block PGE2-glyceryl ester activity. CONCLUSIONS AND IMPLICATIONS: The ability of AGN 204396 to selectively block prostamide responses suggests the existence of prostamide sensitive receptors as entities distinct from receptors recognizing PGF2alpha and PGE2-glyceryl ester.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.